These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

695 related items for PubMed ID: 17196423

  • 1. Effects of osteoporosis medications on bone quality.
    Benhamou CL.
    Joint Bone Spine; 2007 Jan; 74(1):39-47. PubMed ID: 17196423
    [Abstract] [Full Text] [Related]

  • 2. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
    Gallacher SJ, Dixon T.
    Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
    [Abstract] [Full Text] [Related]

  • 3. Teriparatide in bisphosphonate-resistant osteoporosis: microarchitectural changes and clinical results after 6 and 18 months.
    Jobke B, Muche B, Burghardt AJ, Semler J, Link TM, Majumdar S.
    Calcif Tissue Int; 2011 Aug; 89(2):130-9. PubMed ID: 21626160
    [Abstract] [Full Text] [Related]

  • 4. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
    Nakatoh S.
    J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
    [Abstract] [Full Text] [Related]

  • 5. Treatment for osteoporosis in people with ß-thalassaemia.
    Bhardwaj A, Swe KM, Sinha NK, Osunkwo I.
    Cochrane Database Syst Rev; 2016 Mar 10; 3():CD010429. PubMed ID: 26964506
    [Abstract] [Full Text] [Related]

  • 6. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis.
    Finkelstein JS, Wyland JJ, Lee H, Neer RM.
    J Clin Endocrinol Metab; 2010 Apr 10; 95(4):1838-45. PubMed ID: 20164296
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar 10; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Effects of antiresorptive therapy on the structural and material properties of bone strength].
    Kishimoto H.
    Clin Calcium; 2016 Jan 10; 26(1):107-15. PubMed ID: 26728537
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.
    Chesnut CH, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, Azria M, Kriegman A, Olson M, Eriksen EF, Mindeholm L.
    J Bone Miner Res; 2005 Sep 10; 20(9):1548-61. PubMed ID: 16059627
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups.
    Burch J, Rice S, Yang H, Neilson A, Stirk L, Francis R, Holloway P, Selby P, Craig D.
    Health Technol Assess; 2014 Feb 10; 18(11):1-180. PubMed ID: 24534414
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bone quality and osteoporosis therapy.
    Martin RM, Correa PH.
    Arq Bras Endocrinol Metabol; 2010 Mar 10; 54(2):186-99. PubMed ID: 20485908
    [Abstract] [Full Text] [Related]

  • 19. Is cortical bone hip? What determines cortical bone properties?
    Epstein S.
    Bone; 2007 Jul 10; 41(1 Suppl 1):S3-8. PubMed ID: 17466615
    [Abstract] [Full Text] [Related]

  • 20. Effects of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate on cortical and trabecular bone of vertebra and proximal femur in postmenopausal women with fragility fracture: Sub-analysis by quantitative computed tomography from the TERABIT study.
    Takahashi R, Chiba K, Okazaki N, Era M, Yokota K, Yabe Y, Kondo C, Fukuda T, Fukushima K, Kono M, Michikoshi Y, Yamada S, Iida T, Mitsumizo K, Sato S, Doi M, Watanabe K, Ota S, Shiraishi K, Yonekura A, Osaki M.
    Bone; 2024 Oct 10; 187():117189. PubMed ID: 38960296
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.